AURA · Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Market Cap
715M
52 Wk Range
$4.73 - $9.54
Previous Close
$6.98
Open
$6.50
Volume
791,134
Day Range
$6.50 - $6.98
Enterprise Value
445.4M
Cash
297.2M
Avg Qtr Burn
-26.44M
Insider Ownership
2.41%
Institutional Own.
N/A
Qtr Updated
Sep 30th 2026
